Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8156286 | 0.85 | ALDH1A1 (0.73) | TSHRAPOBEC3AHTTAPOBEC3GMAPK1 | |
| SCHEMBL28114733 | 0.85 | ALDH1A1 (0.72) | TSHRAPOBEC3AHTTAPOBEC3GMAPK1 | |
| SCHEMBL29415167 | 0.84 | MAPK1 (0.77) | TSHRAPOBEC3AHTTAPOBEC3GMAPK1 | |
| SCHEMBL335681 | 0.84 | MAPK1 (0.77) | TSHRAPOBEC3AHTTAPOBEC3GMAPK1 | |
| SCHEMBL25606750 | 0.84 | ALDH1A1 (0.51) | TSHRAPOBEC3AHTTAPOBEC3GMAPK1 | |
| SCHEMBL12982799 | 0.83 | LMNA (0.55) | TSHRAPOBEC3AHTTAPOBEC3GCYP1A2 | |
| SCHEMBL644265 | 0.83 | CA12 (0.69) | TSHRHTTMAPK1CYP1A2CYP2C19 | |
| SCHEMBL29688674 | 0.83 | LMNA (0.55) | TSHRAPOBEC3AHTTAPOBEC3GCYP1A2 | |
| Hydrochloric Acid SCHEMBL5154533 | 0.82 | MAPK1 (0.74) | TSHRAPOBEC3AHTTAPOBEC3GMAPK1 | |
| SCHEMBL426745 | 0.81 | MAPT (0.62) | TSHRHTTCYP1A2CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081982-A1 | PREPARATION METHOD FOR FINERENONE KEY INTERMEDIATE | 山东诚创蓝海医药科技有限公司 | 2025-04-24 | — | — | WO | claimed |
| CN-119859112-A | Preparation method of non-neridrone key intermediate | 山东诚创蓝海医药科技有限公司 | 2025-04-22 | — | — | CN | claimed |
| US-10696611-B2 | Adamantane derivative compound | AMOREPACIFIC CORPORATION (KR) | 2020-06-30 | — | — | US | claimed |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2017-10-05 | — | — | US | claimed |
| EP-3187486-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | Amorepacific Corporation (KR) | 2017-07-05 | — | — | EP | claimed |
| WO-2025081982-A1 | PREPARATION METHOD FOR FINERENONE KEY INTERMEDIATE | 山东诚创蓝海医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| WO-2025081982-A1 | PREPARATION METHOD FOR FINERENONE KEY INTERMEDIATE | 山东诚创蓝海医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119859112-A | Preparation method of non-neridrone key intermediate | 山东诚创蓝海医药科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119859112-A | Preparation method of non-neridrone key intermediate | 山东诚创蓝海医药科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-117776973-A | Preparation method of 4-formyl-3-methoxybenzonitrile | 山东特珐曼药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117088884-A | Imidazopyridazine derivatives as GABAA receptor modulators, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-3187486-B1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORP (KR) | 2023-10-18 | — | — | EP | disclosed |
| EP-0702012-B1 | Substituted isoxazole sulfonamides and their use as endothelin antagonists | BRISTOL MYERS SQUIBB CO (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-0921800-A4 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-0921800-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5827869-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-27 | — | — | US | disclosed |
| WO-1997029748-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5612359-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0702012-A1 | Substituted isoxazole sulfonamides and their use as endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696611-B2 | Adamantane derivative compound | ADAM8, BACE1, CYP17A1 | TSHR 4090/4885APOBEC3A 1030/4885HTT 1830/4885 |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | ADAM8, CYP17A1, ADAM10 | TSHR 3845/4885APOBEC3A 1413/4885HTT 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.